Data On Investigational Drug TMC207 For Treatment Of MDR -Tuberculosis, Published In New England Journal Of Medicine (BioresearchOnline)
Interim results from an ongoing phase 2, randomized, placebo-controlled trial of the investigational drug TMC207 for the treatment of multidrug-resistant tuberculosis (MDR-TB) were published in the New England Journal of Medicine recently.If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.

Comments
No comments yet.
Sorry, the comment form is closed at this time.